Stem definition | Drug id | CAS RN |
---|---|---|
4554 | 397864-44-7 |
Dose | Unit | Route |
---|---|---|
0.20 | mg | N |
0.11 | mg | N |
0.60 | mg | Inhal.aerosol |
0.60 | mg | Inhal.powder |
1.50 | mg | Inhal.solution |
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 4.95 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 13.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 10.60 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
April 27, 2007 | FDA | GLAXOSMITHKLINE | |
April 22, 2009 | PMDA | GlaxoSmithKline K.K. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Macular degeneration | 460.12 | 18.99 | 161 | 12134 | 14227 | 50578602 |
Asthma | 455.32 | 18.99 | 278 | 12017 | 89059 | 50503770 |
Wheezing | 359.79 | 18.99 | 210 | 12085 | 61837 | 50530992 |
Obstructive airways disorder | 337.13 | 18.99 | 131 | 12164 | 15521 | 50577308 |
Full blood count abnormal | 198.60 | 18.99 | 102 | 12193 | 23286 | 50569543 |
Nasal congestion | 171.94 | 18.99 | 123 | 12172 | 50997 | 50541832 |
Dyspnoea | 134.54 | 18.99 | 361 | 11934 | 547247 | 50045582 |
Therapeutic product effect incomplete | 115.24 | 18.99 | 126 | 12169 | 91389 | 50501440 |
Bronchial haemorrhage | 112.65 | 18.99 | 26 | 12269 | 494 | 50592335 |
Bronchial neoplasm | 111.90 | 18.99 | 25 | 12270 | 408 | 50592421 |
Gastrooesophageal reflux disease | 102.82 | 18.99 | 109 | 12186 | 76319 | 50516510 |
Nasal turbinate hypertrophy | 101.04 | 18.99 | 25 | 12270 | 645 | 50592184 |
Cough | 99.98 | 18.99 | 196 | 12099 | 241068 | 50351761 |
Sleep disorder due to a general medical condition | 95.54 | 18.99 | 43 | 12252 | 7328 | 50585501 |
Chest discomfort | 95.35 | 18.99 | 115 | 12180 | 92607 | 50500222 |
Endometrial ablation | 94.76 | 18.99 | 25 | 12270 | 838 | 50591991 |
Productive cough | 94.67 | 18.99 | 88 | 12207 | 52606 | 50540223 |
Bronchial disorder | 92.35 | 18.99 | 26 | 12269 | 1116 | 50591713 |
Bronchiectasis | 87.67 | 18.99 | 45 | 12250 | 10238 | 50582591 |
Nasal polyps | 83.14 | 18.99 | 29 | 12266 | 2525 | 50590304 |
Blepharospasm | 82.80 | 18.99 | 30 | 12265 | 2918 | 50589911 |
Hyper IgE syndrome | 79.81 | 18.99 | 19 | 12276 | 415 | 50592414 |
Total lung capacity increased | 79.54 | 18.99 | 21 | 12274 | 706 | 50592123 |
Rhonchi | 78.21 | 18.99 | 27 | 12268 | 2280 | 50590549 |
Asthma-chronic obstructive pulmonary disease overlap syndrome | 78.10 | 18.99 | 19 | 12276 | 456 | 50592373 |
Throat clearing | 77.82 | 18.99 | 23 | 12272 | 1175 | 50591654 |
Respiratory tract inflammation | 75.68 | 18.99 | 19 | 12276 | 521 | 50592308 |
Dust allergy | 74.93 | 18.99 | 19 | 12276 | 543 | 50592286 |
Sputum discoloured | 71.31 | 18.99 | 43 | 12252 | 13352 | 50579477 |
Blood immunoglobulin E increased | 69.99 | 18.99 | 25 | 12270 | 2334 | 50590495 |
Malignant mediastinal neoplasm | 69.95 | 18.99 | 18 | 12277 | 546 | 50592283 |
Dyspnoea exertional | 65.21 | 18.99 | 71 | 12224 | 51162 | 50541667 |
Breath sounds abnormal | 63.26 | 18.99 | 33 | 12262 | 7759 | 50585070 |
Restrictive pulmonary disease | 61.50 | 18.99 | 20 | 12275 | 1404 | 50591425 |
Rhinitis | 61.29 | 18.99 | 33 | 12262 | 8268 | 50584561 |
Taste disorder | 61.21 | 18.99 | 33 | 12262 | 8291 | 50584538 |
Affective disorder | 60.15 | 18.99 | 28 | 12267 | 5153 | 50587676 |
Blood test abnormal | 59.38 | 18.99 | 36 | 12259 | 11283 | 50581546 |
Secretion discharge | 58.85 | 18.99 | 34 | 12261 | 9757 | 50583072 |
Granuloma | 55.61 | 18.99 | 26 | 12269 | 4832 | 50587997 |
Rhinorrhoea | 53.00 | 18.99 | 64 | 12231 | 51519 | 50541310 |
Haemoptysis | 48.40 | 18.99 | 44 | 12251 | 25529 | 50567300 |
Polycystic ovaries | 47.16 | 18.99 | 19 | 12276 | 2465 | 50590364 |
Sleep apnoea syndrome | 47.01 | 18.99 | 42 | 12253 | 23826 | 50569003 |
Chronic obstructive pulmonary disease | 46.46 | 18.99 | 61 | 12234 | 53374 | 50539455 |
Sarcoidosis | 45.80 | 18.99 | 23 | 12272 | 4994 | 50587835 |
Lung hyperinflation | 45.45 | 18.99 | 15 | 12280 | 1103 | 50591726 |
Eczema | 44.82 | 18.99 | 40 | 12255 | 22662 | 50570167 |
Nasal obstruction | 42.52 | 18.99 | 14 | 12281 | 1022 | 50591807 |
Chronic sinusitis | 41.41 | 18.99 | 23 | 12272 | 6122 | 50586707 |
Respiratory disorder | 41.03 | 18.99 | 44 | 12251 | 31143 | 50561686 |
Rhinitis allergic | 40.62 | 18.99 | 24 | 12271 | 7176 | 50585653 |
Lactose intolerance | 39.81 | 18.99 | 17 | 12278 | 2553 | 50590276 |
Eye pruritus | 39.43 | 18.99 | 29 | 12266 | 12505 | 50580324 |
Death | 37.66 | 18.99 | 16 | 12279 | 325363 | 50267466 |
Toxicity to various agents | 37.49 | 18.99 | 4 | 12291 | 212495 | 50380334 |
Sinusitis | 34.23 | 18.99 | 105 | 12190 | 170453 | 50422376 |
Forced expiratory volume decreased | 33.93 | 18.99 | 18 | 12277 | 4376 | 50588453 |
Dyslipidaemia | 33.89 | 18.99 | 20 | 12275 | 5968 | 50586861 |
Herpes zoster | 33.51 | 18.99 | 61 | 12234 | 70725 | 50522104 |
Ligament pain | 33.29 | 18.99 | 8 | 12287 | 182 | 50592647 |
Rales | 31.19 | 18.99 | 23 | 12272 | 9955 | 50582874 |
Weight decreased | 31.12 | 18.99 | 121 | 12174 | 221124 | 50371705 |
Crystal arthropathy | 31.08 | 18.99 | 8 | 12287 | 243 | 50592586 |
Migraine | 30.84 | 18.99 | 61 | 12234 | 75219 | 50517610 |
Ear pruritus | 30.40 | 18.99 | 14 | 12281 | 2512 | 50590317 |
Sneezing | 30.23 | 18.99 | 26 | 12269 | 14018 | 50578811 |
Blood pressure diastolic abnormal | 30.22 | 18.99 | 22 | 12273 | 9339 | 50583490 |
Epilepsy | 29.38 | 18.99 | 31 | 12264 | 21536 | 50571293 |
Bronchitis | 28.68 | 18.99 | 72 | 12223 | 104087 | 50488742 |
Alopecia | 26.84 | 18.99 | 13 | 12282 | 245034 | 50347795 |
Asthmatic crisis | 25.98 | 18.99 | 11 | 12284 | 1617 | 50591212 |
Ankle fracture | 25.81 | 18.99 | 25 | 12270 | 15697 | 50577132 |
Swelling face | 25.74 | 18.99 | 46 | 12249 | 52549 | 50540280 |
Blood pressure systolic increased | 25.58 | 18.99 | 37 | 12258 | 35412 | 50557417 |
Sinus pain | 25.56 | 18.99 | 12 | 12283 | 2249 | 50590580 |
Seasonal allergy | 25.34 | 18.99 | 24 | 12271 | 14652 | 50578177 |
Angioedema | 25.28 | 18.99 | 38 | 12257 | 37638 | 50555191 |
Blood pressure systolic abnormal | 24.62 | 18.99 | 18 | 12277 | 7688 | 50585141 |
Pertussis | 23.71 | 18.99 | 8 | 12287 | 630 | 50592199 |
Arthropathy | 23.22 | 18.99 | 5 | 12290 | 157901 | 50434928 |
Blood pressure diastolic increased | 22.91 | 18.99 | 17 | 12278 | 7426 | 50585403 |
Subclavian vein thrombosis | 21.74 | 18.99 | 10 | 12285 | 1789 | 50591040 |
Sensitivity to weather change | 21.43 | 18.99 | 15 | 12280 | 5986 | 50586843 |
Stress | 21.32 | 18.99 | 43 | 12252 | 53750 | 50539079 |
Cardiac murmur | 21.27 | 18.99 | 19 | 12276 | 10765 | 50582064 |
Sinus tachycardia | 21.11 | 18.99 | 26 | 12269 | 21328 | 50571501 |
Stent placement | 20.82 | 18.99 | 12 | 12283 | 3426 | 50589403 |
Lung neoplasm malignant | 20.63 | 18.99 | 22 | 12273 | 15462 | 50577367 |
Eosinophilia | 20.55 | 18.99 | 24 | 12271 | 18628 | 50574201 |
Paraesthesia | 20.45 | 18.99 | 70 | 12225 | 120173 | 50472656 |
Eosinophil count increased | 20.34 | 18.99 | 17 | 12278 | 8813 | 50584016 |
Radioallergosorbent test positive | 20.30 | 18.99 | 4 | 12291 | 34 | 50592795 |
Dyspnoea at rest | 20.16 | 18.99 | 12 | 12283 | 3635 | 50589194 |
Restless legs syndrome | 20.15 | 18.99 | 22 | 12273 | 15875 | 50576954 |
Chondrocalcinosis pyrophosphate | 19.81 | 18.99 | 8 | 12287 | 1044 | 50591785 |
Respiratory gas exchange disorder | 19.69 | 18.99 | 6 | 12289 | 340 | 50592489 |
Oral pruritus | 19.26 | 18.99 | 9 | 12286 | 1669 | 50591160 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Asthma | 259.88 | 20.73 | 130 | 5897 | 33719 | 29534781 |
Wheezing | 184.88 | 20.73 | 103 | 5924 | 33137 | 29535363 |
Nasal polyps | 81.39 | 20.73 | 25 | 6002 | 1744 | 29566756 |
Appendicolith | 79.39 | 20.73 | 29 | 5998 | 3451 | 29565049 |
Therapeutic product effect incomplete | 73.13 | 20.73 | 62 | 5965 | 39243 | 29529257 |
Sleep disorder due to a general medical condition | 70.96 | 20.73 | 26 | 6001 | 3120 | 29565380 |
Obstructive airways disorder | 69.03 | 20.73 | 37 | 5990 | 10979 | 29557521 |
Nasal congestion | 67.20 | 20.73 | 44 | 5983 | 18835 | 29549665 |
Foetal malformation | 66.81 | 20.73 | 13 | 6014 | 125 | 29568375 |
Trisomy 18 | 62.26 | 20.73 | 13 | 6014 | 183 | 29568317 |
Appendicitis | 53.63 | 20.73 | 29 | 5998 | 8750 | 29559750 |
Cough | 52.36 | 20.73 | 93 | 5934 | 126634 | 29441866 |
Full blood count abnormal | 51.02 | 20.73 | 34 | 5993 | 14979 | 29553521 |
Rhinitis | 50.74 | 20.73 | 23 | 6004 | 4755 | 29563745 |
Sputum discoloured | 49.59 | 20.73 | 25 | 6002 | 6538 | 29561962 |
Seasonal allergy | 46.22 | 20.73 | 22 | 6005 | 5080 | 29563420 |
Ocular discomfort | 41.98 | 20.73 | 15 | 6012 | 1674 | 29566826 |
Middle insomnia | 40.96 | 20.73 | 21 | 6006 | 5687 | 29562813 |
Stress | 40.13 | 20.73 | 34 | 5993 | 21456 | 29547044 |
Dyspnoea | 39.00 | 20.73 | 150 | 5877 | 326582 | 29241918 |
Eye pruritus | 37.18 | 20.73 | 18 | 6009 | 4314 | 29564186 |
Chest discomfort | 36.67 | 20.73 | 46 | 5981 | 45937 | 29522563 |
Anosmia | 36.00 | 20.73 | 14 | 6013 | 1977 | 29566523 |
Nasal oedema | 35.94 | 20.73 | 9 | 6018 | 293 | 29568207 |
Forced expiratory volume decreased | 34.56 | 20.73 | 15 | 6012 | 2798 | 29565702 |
Loss of personal independence in daily activities | 33.33 | 20.73 | 33 | 5994 | 25407 | 29543093 |
Cardiogenic shock | 33.07 | 20.73 | 29 | 5998 | 19161 | 29549339 |
Productive cough | 32.79 | 20.73 | 36 | 5991 | 31223 | 29537277 |
Pharyngeal paraesthesia | 32.18 | 20.73 | 9 | 6018 | 451 | 29568049 |
SARS-CoV-2 sepsis | 32.07 | 20.73 | 7 | 6020 | 123 | 29568377 |
Glaucoma | 32.06 | 20.73 | 18 | 6009 | 5839 | 29562661 |
Central obesity | 31.80 | 20.73 | 9 | 6018 | 471 | 29568029 |
Victim of child abuse | 30.80 | 20.73 | 10 | 6017 | 835 | 29567665 |
Eczema | 30.27 | 20.73 | 24 | 6003 | 13802 | 29554698 |
Nasal disorder | 29.10 | 20.73 | 11 | 6016 | 1438 | 29567062 |
Dermatitis atopic | 27.81 | 20.73 | 12 | 6015 | 2207 | 29566293 |
Dermatitis allergic | 27.18 | 20.73 | 16 | 6011 | 5672 | 29562828 |
Polyp | 26.70 | 20.73 | 13 | 6014 | 3152 | 29565348 |
Nasal septum deviation | 25.67 | 20.73 | 9 | 6018 | 950 | 29567550 |
Gastroenteritis eosinophilic | 25.22 | 20.73 | 6 | 6021 | 157 | 29568343 |
Eosinophilic pneumonia chronic | 25.07 | 20.73 | 6 | 6021 | 161 | 29568339 |
Ocular hyperaemia | 24.74 | 20.73 | 18 | 6009 | 9109 | 29559391 |
Lung diffusion disorder | 23.23 | 20.73 | 5 | 6022 | 82 | 29568418 |
Cortisol decreased | 23.02 | 20.73 | 8 | 6019 | 823 | 29567677 |
Faecal calprotectin | 22.83 | 20.73 | 4 | 6023 | 20 | 29568480 |
Alpha 2 globulin decreased | 22.83 | 20.73 | 4 | 6023 | 20 | 29568480 |
Otosalpingitis | 22.83 | 20.73 | 4 | 6023 | 20 | 29568480 |
Sex hormone binding globulin decreased | 22.67 | 20.73 | 4 | 6023 | 21 | 29568479 |
Free androgen index decreased | 22.67 | 20.73 | 4 | 6023 | 21 | 29568479 |
Androgen insensitivity syndrome | 22.51 | 20.73 | 4 | 6023 | 22 | 29568478 |
Viral acanthoma | 22.51 | 20.73 | 4 | 6023 | 22 | 29568478 |
Testicular microlithiasis | 22.22 | 20.73 | 4 | 6023 | 24 | 29568476 |
Conjunctivitis | 22.19 | 20.73 | 16 | 6011 | 7982 | 29560518 |
Dehydroepiandrosterone decreased | 22.08 | 20.73 | 4 | 6023 | 25 | 29568475 |
Urine calcium/creatinine ratio increased | 22.08 | 20.73 | 4 | 6023 | 25 | 29568475 |
Blood test abnormal | 21.92 | 20.73 | 14 | 6013 | 5735 | 29562765 |
Ventricular fibrillation | 21.59 | 20.73 | 21 | 6006 | 15812 | 29552688 |
Rhinorrhoea | 21.21 | 20.73 | 24 | 6003 | 21495 | 29547005 |
Creatinine urine decreased | 20.79 | 20.73 | 4 | 6023 | 36 | 29568464 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Asthma | 580.85 | 16.97 | 339 | 16168 | 94886 | 64387339 |
Wheezing | 486.20 | 16.97 | 285 | 16222 | 80294 | 64401931 |
Obstructive airways disorder | 357.34 | 16.97 | 155 | 16352 | 23030 | 64459195 |
Full blood count abnormal | 241.25 | 16.97 | 128 | 16379 | 29629 | 64452596 |
Nasal congestion | 229.46 | 16.97 | 159 | 16348 | 59499 | 64422726 |
Therapeutic product effect incomplete | 162.09 | 16.97 | 164 | 16343 | 103318 | 64378907 |
Nasal polyps | 150.30 | 16.97 | 50 | 16457 | 3579 | 64478646 |
Dyspnoea | 144.23 | 16.97 | 456 | 16051 | 718218 | 63764007 |
Cough | 138.56 | 16.97 | 264 | 16243 | 301884 | 64180341 |
Sleep disorder due to a general medical condition | 133.16 | 16.97 | 57 | 16450 | 8177 | 64474048 |
Chest discomfort | 114.96 | 16.97 | 145 | 16362 | 115961 | 64366264 |
Productive cough | 112.69 | 16.97 | 115 | 16392 | 73088 | 64409137 |
Bronchial neoplasm | 110.03 | 16.97 | 25 | 16482 | 418 | 64481807 |
Nasal turbinate hypertrophy | 108.70 | 16.97 | 26 | 16481 | 549 | 64481676 |
Sputum discoloured | 106.96 | 16.97 | 63 | 16444 | 17793 | 64464432 |
Rhinitis | 106.55 | 16.97 | 53 | 16454 | 10712 | 64471513 |
Gastrooesophageal reflux disease | 100.58 | 16.97 | 115 | 16392 | 83028 | 64399197 |
Endometrial ablation | 95.31 | 16.97 | 25 | 16482 | 776 | 64481449 |
Rhonchi | 90.92 | 16.97 | 34 | 16473 | 3429 | 64478796 |
Bronchial haemorrhage | 89.27 | 16.97 | 26 | 16481 | 1196 | 64481029 |
Bronchiectasis | 87.62 | 16.97 | 51 | 16456 | 14089 | 64468136 |
Throat clearing | 86.94 | 16.97 | 26 | 16481 | 1312 | 64480913 |
Blood test abnormal | 81.04 | 16.97 | 47 | 16460 | 12896 | 64469329 |
Hyper IgE syndrome | 76.34 | 16.97 | 19 | 16488 | 476 | 64481749 |
Bronchial disorder | 75.23 | 16.97 | 26 | 16481 | 2089 | 64480136 |
Total lung capacity increased | 74.27 | 16.97 | 20 | 16487 | 688 | 64481537 |
Eczema | 71.61 | 16.97 | 60 | 16447 | 29660 | 64452565 |
Blepharospasm | 70.29 | 16.97 | 28 | 16479 | 3347 | 64478878 |
Appendicolith | 69.54 | 16.97 | 28 | 16479 | 3441 | 64478784 |
Rhinorrhoea | 69.22 | 16.97 | 81 | 16426 | 59888 | 64422337 |
Eye pruritus | 68.90 | 16.97 | 42 | 16465 | 12617 | 64469608 |
Respiratory tract inflammation | 67.53 | 16.97 | 19 | 16488 | 771 | 64481454 |
Restrictive pulmonary disease | 66.94 | 16.97 | 24 | 16483 | 2148 | 64480077 |
Malignant mediastinal neoplasm | 65.14 | 16.97 | 17 | 16490 | 517 | 64481708 |
Affective disorder | 63.94 | 16.97 | 32 | 16475 | 6548 | 64475677 |
Blood immunoglobulin E increased | 63.43 | 16.97 | 27 | 16480 | 3817 | 64478408 |
Toxicity to various agents | 63.23 | 16.97 | 9 | 16498 | 363504 | 64118721 |
Forced expiratory volume decreased | 62.65 | 16.97 | 32 | 16475 | 6835 | 64475390 |
Dust allergy | 62.14 | 16.97 | 19 | 16488 | 1034 | 64481191 |
Breath sounds abnormal | 61.68 | 16.97 | 38 | 16469 | 11631 | 64470594 |
Stress | 58.89 | 16.97 | 75 | 16432 | 60459 | 64421766 |
Seasonal allergy | 54.01 | 16.97 | 35 | 16472 | 11691 | 64470534 |
Secretion discharge | 53.36 | 16.97 | 35 | 16472 | 11929 | 64470296 |
Taste disorder | 53.14 | 16.97 | 32 | 16475 | 9401 | 64472824 |
Asthma-chronic obstructive pulmonary disease overlap syndrome | 52.63 | 16.97 | 17 | 16490 | 1108 | 64481117 |
Sleep apnoea syndrome | 49.78 | 16.97 | 49 | 16458 | 29783 | 64452442 |
Granuloma | 49.39 | 16.97 | 27 | 16480 | 6614 | 64475611 |
Polycystic ovaries | 48.81 | 16.97 | 19 | 16488 | 2136 | 64480089 |
Rhinitis allergic | 47.05 | 16.97 | 28 | 16479 | 8050 | 64474175 |
Sinusitis | 46.33 | 16.97 | 110 | 16397 | 145818 | 64336407 |
Respiratory disorder | 45.41 | 16.97 | 51 | 16456 | 36060 | 64446165 |
Dyspnoea exertional | 44.72 | 16.97 | 73 | 16434 | 73657 | 64408568 |
Middle insomnia | 44.06 | 16.97 | 32 | 16475 | 12845 | 64469380 |
Lung hyperinflation | 42.95 | 16.97 | 16 | 16491 | 1596 | 64480629 |
Lactose intolerance | 42.94 | 16.97 | 17 | 16490 | 1999 | 64480226 |
Death | 39.79 | 16.97 | 39 | 16468 | 482666 | 63999559 |
Migraine | 39.29 | 16.97 | 63 | 16444 | 62614 | 64419611 |
Bronchitis | 38.96 | 16.97 | 86 | 16421 | 108657 | 64373568 |
Chronic obstructive pulmonary disease | 38.64 | 16.97 | 67 | 16440 | 70981 | 64411244 |
Anosmia | 38.60 | 16.97 | 20 | 16487 | 4397 | 64477828 |
Nasal obstruction | 38.09 | 16.97 | 14 | 16493 | 1345 | 64480880 |
Blood pressure diastolic increased | 37.43 | 16.97 | 27 | 16480 | 10725 | 64471500 |
Chronic sinusitis | 37.15 | 16.97 | 22 | 16485 | 6270 | 64475955 |
Loss of personal independence in daily activities | 36.40 | 16.97 | 66 | 16441 | 72388 | 64409837 |
Lower respiratory tract infection | 36.38 | 16.97 | 77 | 16430 | 94537 | 64387688 |
Polyp | 35.95 | 16.97 | 22 | 16485 | 6651 | 64475574 |
Appendicitis | 33.94 | 16.97 | 28 | 16479 | 13541 | 64468684 |
Swelling face | 33.75 | 16.97 | 57 | 16450 | 59109 | 64423116 |
Herpes zoster | 33.45 | 16.97 | 67 | 16440 | 79120 | 64403105 |
Sarcoidosis | 32.44 | 16.97 | 20 | 16487 | 6126 | 64476099 |
Ligament pain | 32.35 | 16.97 | 8 | 16499 | 195 | 64482030 |
Eosinophilic pneumonia chronic | 32.21 | 16.97 | 9 | 16498 | 356 | 64481869 |
Anaemia | 31.87 | 16.97 | 30 | 16477 | 378650 | 64103575 |
Thrombocytopenia | 31.69 | 16.97 | 9 | 16498 | 223792 | 64258433 |
Cardiac murmur | 31.32 | 16.97 | 25 | 16482 | 11538 | 64470687 |
Blood pressure diastolic abnormal | 30.66 | 16.97 | 25 | 16482 | 11892 | 64470333 |
Nasal oedema | 30.54 | 16.97 | 11 | 16496 | 997 | 64481228 |
Haemoptysis | 30.33 | 16.97 | 49 | 16458 | 48999 | 64433226 |
SARS-CoV-2 sepsis | 30.32 | 16.97 | 7 | 16500 | 126 | 64482099 |
Sneezing | 29.14 | 16.97 | 27 | 16480 | 15224 | 64467001 |
Ear pruritus | 29.02 | 16.97 | 14 | 16493 | 2646 | 64479579 |
Victim of child abuse | 28.26 | 16.97 | 10 | 16497 | 861 | 64481364 |
Weight decreased | 28.23 | 16.97 | 146 | 16361 | 285593 | 64196632 |
Ankle fracture | 28.02 | 16.97 | 26 | 16481 | 14684 | 64467541 |
Acute kidney injury | 27.91 | 16.97 | 45 | 16462 | 449195 | 64033030 |
Asthmatic crisis | 27.87 | 16.97 | 12 | 16495 | 1744 | 64480481 |
Ocular discomfort | 26.30 | 16.97 | 15 | 16492 | 3984 | 64478241 |
Oropharyngeal pain | 26.06 | 16.97 | 65 | 16442 | 88802 | 64393423 |
Blood pressure systolic increased | 26.05 | 16.97 | 46 | 16461 | 49407 | 64432818 |
Atopy | 25.55 | 16.97 | 7 | 16500 | 257 | 64481968 |
Neutropenia | 25.27 | 16.97 | 15 | 16492 | 239609 | 64242616 |
Dehydration | 25.16 | 16.97 | 12 | 16495 | 216751 | 64265474 |
Dyslipidaemia | 25.07 | 16.97 | 20 | 16487 | 9222 | 64473003 |
Eosinophilia | 24.86 | 16.97 | 39 | 16468 | 38037 | 64444188 |
Epilepsy | 24.23 | 16.97 | 36 | 16471 | 33495 | 64448730 |
Cardiac arrest | 24.14 | 16.97 | 5 | 16502 | 154059 | 64328166 |
Throat irritation | 23.46 | 16.97 | 35 | 16472 | 32676 | 64449549 |
Crepitations | 23.35 | 16.97 | 18 | 16489 | 7897 | 64474328 |
Haemoglobin decreased | 22.33 | 16.97 | 11 | 16496 | 195052 | 64287173 |
Nasal disorder | 22.21 | 16.97 | 12 | 16495 | 2872 | 64479353 |
Cortisol decreased | 21.92 | 16.97 | 10 | 16497 | 1667 | 64480558 |
Blood pressure systolic abnormal | 21.75 | 16.97 | 19 | 16488 | 9923 | 64472302 |
Rales | 21.74 | 16.97 | 23 | 16484 | 15206 | 64467019 |
Gastroenteritis eosinophilic | 21.70 | 16.97 | 6 | 16501 | 228 | 64481997 |
Platelet count decreased | 21.52 | 16.97 | 8 | 16499 | 167703 | 64314522 |
Lung neoplasm malignant | 21.52 | 16.97 | 27 | 16480 | 21421 | 64460804 |
Sensitivity to weather change | 21.43 | 16.97 | 16 | 16491 | 6698 | 64475527 |
Eosinophil count increased | 21.37 | 16.97 | 22 | 16485 | 14090 | 64468135 |
Pertussis | 21.33 | 16.97 | 8 | 16499 | 813 | 64481412 |
Paraesthesia | 21.10 | 16.97 | 79 | 16428 | 134443 | 64347782 |
Pharyngeal paraesthesia | 20.64 | 16.97 | 10 | 16497 | 1907 | 64480318 |
Sinus pain | 20.57 | 16.97 | 11 | 16496 | 2578 | 64479647 |
Lung diffusion disorder | 20.45 | 16.97 | 5 | 16502 | 116 | 64482109 |
Autism spectrum disorder | 20.27 | 16.97 | 8 | 16499 | 933 | 64481292 |
Radioallergosorbent test positive | 20.19 | 16.97 | 4 | 16503 | 33 | 64482192 |
Central obesity | 20.04 | 16.97 | 9 | 16498 | 1446 | 64480779 |
Influenza | 19.66 | 16.97 | 66 | 16441 | 106465 | 64375760 |
Eosinophilic granulomatosis with polyangiitis | 19.47 | 16.97 | 11 | 16496 | 2871 | 64479354 |
Gastrointestinal haemorrhage | 19.32 | 16.97 | 5 | 16502 | 132307 | 64349918 |
Cardiac failure congestive | 18.95 | 16.97 | 5 | 16502 | 130575 | 64351650 |
Eosinophilic bronchitis | 18.91 | 16.97 | 6 | 16501 | 369 | 64481856 |
Ocular hyperaemia | 18.91 | 16.97 | 26 | 16481 | 22538 | 64459687 |
Respiratory failure | 18.58 | 16.97 | 9 | 16498 | 161174 | 64321051 |
Overdose | 18.26 | 16.97 | 9 | 16498 | 159557 | 64322668 |
Ovarian cyst | 18.19 | 16.97 | 18 | 16489 | 11000 | 64471225 |
Oral pruritus | 18.19 | 16.97 | 9 | 16498 | 1796 | 64480429 |
Sinus disorder | 18.11 | 16.97 | 22 | 16485 | 16886 | 64465339 |
Febrile neutropenia | 18.08 | 16.97 | 13 | 16494 | 187644 | 64294581 |
Asthenia | 17.44 | 16.97 | 54 | 16453 | 427990 | 64054235 |
Respiratory tract infection | 17.43 | 16.97 | 33 | 16474 | 37374 | 64444851 |
Paraesthesia oral | 17.28 | 16.97 | 19 | 16488 | 13112 | 64469113 |
Malignant neoplasm progression | 17.00 | 16.97 | 4 | 16503 | 112867 | 64369358 |
None
Source | Code | Description |
---|---|---|
ATC | D07AC17 | DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, PLAIN Corticosteroids, potent (group III) |
ATC | R01AD08 | RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Corticosteroids |
ATC | R01AD12 | RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Corticosteroids |
ATC | R01AD58 | RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Corticosteroids |
ATC | R03AK06 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics |
ATC | R03AK10 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics |
ATC | R03AK11 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics |
ATC | R03AL08 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
ATC | R03BA05 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Glucocorticoids |
ATC | R03BA09 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS Glucocorticoids |
FDA MoA | N0000175450 | Corticosteroid Hormone Receptor Agonists |
FDA EPC | N0000175576 | Corticosteroid |
CHEBI has role | CHEBI:49167 | anti-asthmatic drugs |
CHEBI has role | CHEBI:50857 | anti-allergic drugs |
MeSH PA | D018926 | Anti-Allergic Agents |
MeSH PA | D018927 | Anti-Asthmatic Agents |
MeSH PA | D000893 | Anti-Inflammatory Agents |
MeSH PA | D001993 | Bronchodilator Agents |
MeSH PA | D003879 | Dermatologic Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D019141 | Respiratory System Agents |
CHEBI has role | CHEBI:50266 | Prodrugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic obstructive lung disease | indication | 13645005 | DOID:3083 |
Allergic rhinitis | indication | 61582004 | |
Chronic bronchitis | indication | 63480004 | DOID:6132 |
Pulmonary emphysema | indication | 87433001 | |
Asthma | indication | 195967001 | DOID:2841 |
Chronic Non-Allergic Rhinitis | indication | ||
Mycosis | contraindication | 3218000 | DOID:1564 |
Ocular hypertension | contraindication | 4210003 | DOID:9282 |
Epistaxis | contraindication | 12441001 | |
Measles | contraindication | 14189004 | DOID:8622 |
Disease caused by parasite | contraindication | 17322007 | |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Viral disease | contraindication | 34014006 | DOID:934 |
Hypercortisolism | contraindication | 47270006 | |
Perforation of nasal septum | contraindication | 80142000 | |
Bacterial infectious disease | contraindication | 87628006 | |
Operation on nose | contraindication | 88733004 | |
Bilateral cataracts | contraindication | 95722004 | |
Pulmonary tuberculosis | contraindication | 154283005 | DOID:2957 |
Ophthalmic herpes simplex | contraindication | 186542001 | |
Varicella-zoster virus infection | contraindication | 309465005 | |
Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
Exposure to varicella | contraindication | 444453009 | |
Nasal Candidiasis | contraindication | ||
Nasal Trauma | contraindication | ||
Nasal Septal Ulcers | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.49 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | RE44874 | March 23, 2023 | FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | RE44874 | March 23, 2023 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.2MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | April 30, 2015 | RX | POWDER | INHALATION | RE44874 | March 23, 2023 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | RE44874 | March 23, 2023 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | RE44874 | March 23, 2023 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA |
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 9, 2020 | RX | POWDER | INHALATION | RE44874 | March 23, 2023 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | 8309572 | April 27, 2025 | METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION |
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 9, 2020 | RX | POWDER | INHALATION | 8309572 | April 27, 2025 | METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER |
0.2MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | April 30, 2015 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA |
0.2MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | April 30, 2015 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.2MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | April 30, 2015 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 18 YRS AND OLDER, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 9, 2020 | RX | POWDER | INHALATION | 7439393 | May 21, 2025 | MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 18 YRS AND OLDER, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | 8183257 | July 27, 2025 | METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA INHALATION |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | 8183257 | July 27, 2025 | METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION |
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 9, 2020 | RX | POWDER | INHALATION | 8183257 | July 27, 2025 | METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 8511304 | June 14, 2027 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 8511304 | June 14, 2027 | LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS |
0.2MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | April 30, 2015 | RX | POWDER | INHALATION | 8511304 | June 14, 2027 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | 8511304 | June 14, 2027 | METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD |
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 9, 2020 | RX | POWDER | INHALATION | 8511304 | June 14, 2027 | METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 11116721 | Feb. 26, 2029 | INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS |
0.1MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | May 10, 2013 | RX | POWDER | INHALATION | 11116721 | Feb. 26, 2029 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.2MG/INH;EQ 0.025MG BASE/INH | BREO ELLIPTA | GLAXO GRP LTD | N204275 | April 30, 2015 | RX | POWDER | INHALATION | 11116721 | Feb. 26, 2029 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | 11090294 | Nov. 29, 2030 | MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) COMPRISING THE ONCE PER DAY ADMINISTRATION OF TRELEGY ELLIPTA, 100 MCG FLUTICASONE FUROATE/62.5 MCG UMECLIDINIUM/25 MCG VILANTEROL |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 18, 2017 | RX | POWDER | INHALATION | Sept. 9, 2023 | MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER |
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | TRELEGY ELLIPTA | GLAXOSMITHKLINE | N209482 | Sept. 9, 2020 | RX | POWDER | INHALATION | Sept. 9, 2023 | NEW STRENGTH |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Glucocorticoid receptor | Nuclear hormone receptor | AGONIST | IC50 | 10.12 | CHEMBL | CHEMBL | |||
Mineralocorticoid receptor | Nuclear hormone receptor | IC50 | 6.83 | CHEMBL | |||||
Progesterone receptor | Nuclear hormone receptor | IC50 | 7.68 | CHEMBL | |||||
Androgen receptor | Transcription factor | IC50 | 5.73 | CHEMBL | |||||
Glucocorticoid receptor | Transcription factor | IC50 | 8.30 | CHEMBL |
ID | Source |
---|---|
D06315 | KEGG_DRUG |
4026165 | VUID |
N0000179800 | NUI |
4020529 | VANDF |
4026165 | VANDF |
CHEBI:74899 | CHEBI |
CHEBI:5134 | CHEBI |
GW6 | PDB_CHEM_ID |
CHEMBL1676 | ChEMBL_ID |
C523187 | MESH_SUPPLEMENTAL_RECORD_UI |
10892 | IUPHAR_LIGAND_ID |
6699 | IUPHAR_LIGAND_ID |
8521 | INN_ID |
90566-53-3 | SECONDARY_CAS_RN |
DB08906 | DRUGBANK_ID |
JS86977WNV | UNII |
9854489 | PUBCHEM_CID |
5311101 | PUBCHEM_CID |
DB13867 | DRUGBANK_ID |
41126 | RXNORM |
109674 | MMSL |
23848 | MMSL |
51966 | MMSL |
d01296 | MMSL |
004952 | NDDF |
012173 | NDDF |
108632003 | SNOMEDCT_US |
397192001 | SNOMEDCT_US |
426409006 | SNOMEDCT_US |
C1948374 | UMLSCUI |
C0082607 | UMLSCUI |
CHEMBL1201396 | ChEMBL_ID |
5636 | INN_ID |
D000068298 | MESH_DESCRIPTOR_UI |
CUT2W21N7U | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
FLONASE SENSIMISTALLERGY RELIEF | HUMAN OTC DRUG LABEL | 1 | 0135-0615 | SPRAY, METERED | 27.50 ug | NASAL | NDA | 16 sections |
FLONASE SENSIMISTALLERGY RELIEF | HUMAN OTC DRUG LABEL | 1 | 0135-0616 | SPRAY, METERED | 27.50 ug | NASAL | NDA | 16 sections |
Breo Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0859 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 26 sections |
Breo Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0859 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 26 sections |
Arnuity Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0874 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Arnuity Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0876 | POWDER | 200 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Breo Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0882 | POWDER | 200 ug | RESPIRATORY (INHALATION) | NDA | 26 sections |
Breo Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0882 | POWDER | 200 ug | RESPIRATORY (INHALATION) | NDA | 26 sections |
Trelegy Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0173-0887 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Trelegy Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0173-0887 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Arnuity Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0888 | POWDER | 50 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Trelegy Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0173-0893 | POWDER | 200 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Trelegy Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0173-0893 | POWDER | 200 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
FLONASE SENSIMISTALLERGY RELIEF | HUMAN OTC DRUG LABEL | 1 | 50090-5967 | SPRAY, METERED | 27.50 ug | NASAL | NDA | 17 sections |
Veramyst | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6168 | SPRAY, METERED | 27.50 ug | NASAL | NDA | 27 sections |
Fluticasone Furoate and Vilanterol | HUMAN PRESCRIPTION DRUG LABEL | 2 | 66993-135 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA authorized generic | 26 sections |
Fluticasone Furoate and Vilanterol | HUMAN PRESCRIPTION DRUG LABEL | 2 | 66993-136 | POWDER | 200 ug | RESPIRATORY (INHALATION) | NDA authorized generic | 26 sections |
Breo Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70518-2028 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |
Breo Ellipta | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70518-2028 | POWDER | 100 ug | RESPIRATORY (INHALATION) | NDA | 27 sections |